In This Article:
The fact that multiple Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. When analyzing insider transactions, it is usually more valuable to know whether insiders are buying versus knowing if they are selling, as the latter sends an ambiguous message. However, when multiple insiders sell stock over a specific duration, shareholders should take notice as that could possibly be a red flag.
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.
View our latest analysis for Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Insider Transactions Over The Last Year
In the last twelve months, the biggest single sale by an insider was when the Executive VP and GM of Industrial Operations & Product Supply, Daniel Van Plew, sold US$9.8m worth of shares at a price of US$952 per share. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. It's of some comfort that this sale was conducted at a price well above the current share price, which is US$710. So it is hard to draw any strong conclusion from it.
Insiders in Regeneron Pharmaceuticals didn't buy any shares in the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
I will like Regeneron Pharmaceuticals better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.
Insider Ownership Of Regeneron Pharmaceuticals
Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. Regeneron Pharmaceuticals insiders own about US$2.7b worth of shares (which is 3.6% of the company). I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.
So What Does This Data Suggest About Regeneron Pharmaceuticals Insiders?
It doesn't really mean much that no insider has traded Regeneron Pharmaceuticals shares in the last quarter. While we feel good about high insider ownership of Regeneron Pharmaceuticals, we can't say the same about the selling of shares. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.